Table 1 Model discrimination using Harrell’s concordance index (c-index) to evaluate the prognostic performance of the risk models for predicting distant recurrence-free survival (DRFS)
From: Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors
Cox models | A | B | C | D |
|---|---|---|---|---|
DRFS ~ | RCB-II/III | RCB-II/III + ctDNA T0 | RCB-II/III + ctDNA T3 | RCB-II/III + ctDNA dynamics (T0-T3) |
Predictors | RCB-II vs. RCB-III | RCB − II/ctDNA+ vs. RCB-II/ctDNA- vs. RCB-III/ctDNA+ vs. RCB-III/ctDNA- | RCB − II/ctDNA+ vs. RCB-II/ctDNA- vs. RCB-III/ctDNA+ vs. RCB-III/ctDNA- | Persistent negative vs. Cleared at T1 vs.Cleared at T2 vs.Cleared at T3 vs. No clearance at T3 |
Number of patients | 249 | 249 | 249 | 249 |
Number of events | 66 | 66 | 66 | 66 |
ctDNA time points | - | Pretretment (T0) | Post-NAT (T3) | Pretreatment (T0), Week 3 (T1), Week 12 (T2), Post-NAT (T3) |
C-index | 0.75 | 0.80 | 0.81 | 0.84 |
Lower 95% CI | 0.65 | 0.73 | 0.74 | 0.79 |
Upper 95% CI | 0.84 | 0.87 | 0.87 | 0.90 |
